Neurocrine Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	2,861	2,355	1,887	1,489	1,134
Revenue Growth (YoY)	21.45%	24.81%	26.76%	31.34%	8.38%
Cost of Revenue	52.1	34	39.7	23.2	14.3
Gross Profit	2,808	2,321	1,847	1,466	1,119
Selling, General & Admin	1,156	1,007	887.6	752.7	583.3
Research & Development	1,033	743.6	708.9	463.8	433.4
Operating Income	619.1	570.5	250.9	249	102.5
Interest Income	90.3	91	52.8	4.1	3.8
Interest Expense	-	-138.4	-	-70	-25.8
Other Non-Operating Income (Expense)	-4	-37.1	28.4	30.8	20.9
Total Non-Operating Income (Expense)	86.3	-84.5	81.2	-35.1	-1.1
Pretax Income	705.4	486	332.1	213.9	101.4
Provision for Income Taxes	226.8	144.7	82.4	59.4	11.8
Net Income	478.6	341.3	249.7	154.5	89.6
Net Income to Common	478.6	341.3	249.7	154.5	89.6
Net Income Growth	40.23%	36.68%	61.62%	72.43%	-78.00%
Shares Outstanding (Basic)	100	100	98	96	95
Shares Outstanding (Diluted)	103	104	101	99	98
Shares Change (YoY)	-1.16%	2.67%	2.12%	1.02%	0.10%
EPS (Basic)	4.81	3.40	2.56	1.61	0.95
EPS (Diluted)	4.67	3.29	2.47	1.56	0.92
EPS Growth	41.95%	33.20%	58.33%	69.56%	-77.89%
Free Cash Flow	748.7	557.2	361.6	322.9	233.1
Free Cash Flow Growth	34.37%	54.09%	11.98%	38.52%	7.12%
Free Cash Flow Per Share	7.30	5.37	3.58	3.26	2.38
Gross Margin	98.18%	98.56%	97.90%	98.44%	98.74%
Operating Margin	21.64%	24.22%	13.30%	16.73%	9.04%
Profit Margin	16.73%	14.49%	13.23%	10.38%	7.90%
FCF Margin	26.17%	23.66%	19.16%	21.69%	20.56%
EBITDA	649.2	597.6	272.2	264.6	113.4
EBITDA Margin	22.70%	25.37%	14.42%	17.77%	10.00%
EBIT	619.1	570.5	250.9	249	102.5
EBIT Margin	21.64%	24.22%	13.30%	16.73%	9.04%
Effective Tax Rate	32.15%	29.77%	24.81%	27.77%	11.64%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.